Thus NK cells may be a suitable choice of effector cells to combat minimal residual disease after an induction chemotherapy.[3] CD8+ T cells, however, are frequently present in cancer tissues in abundance, have a greater intrinsic cytotoxic potential than NK cells, and are capable of more prolonged serial lysis.[43, 44] CTLs are therefore a particularly desirable class of cytolytic effectors for cancer therapy. This evidence concerns the gene CD8A and cancer.